Quick Search 
Drugs of the Future
Register or sign in

  
 
  
Drugs Fut 2006, 31(9): 811
ISSN 0377-8282
Copyright 2006 Clarivate Analytics
CCC: 0377-8282
DOI: 10.1358/dof.2006.031.09.1025670
 
 
FX06 (fibrin-derived peptide Bbeta15-42) - A potential candidate for myocardial reperfusion therapy
Henning, R., Zacharowski, K., Petzelbauer, P.
 
 
FX06 (fibrin derived peptide Bb15-42) is a promising new drug candidate indicated for the prevention of reperfusion injury in patients undergoing primary percutaneous intervention (PCI) for acute myocardial infarction (AMI). This novel peptide has been shown to prevent myocardial reperfusion injury in a number of acute and chronic animal models for this disease when given as a single bolus injection at the time of reperfusion. FX06 has a novel mechanism of action: it is a competitive inhibitor of the binding of fibrin E1 fragments to vascular endothelial (VE)-cadherin. Through this inhibition, it potently blocks the transmigration of inflammatory leukocytes through the endothelial barrier and prevents the downstream release of tissue-damaging mediators. FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development.


Full Text: HTMLPDF 
 
  



© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy